PEG-MGF is a synthetic, pegylated version of a growth-factor peptide connected to muscle and tissue-repair biology. It comes from a splice variant of IGF-1 (called MGF) that the body makes after muscle stress to wake up muscle stem cells. It is not an approved medication, and there is no validated human dose and no identified human exposure data.
PEG-MGF sits in the IGF-1 splice-variant / mechano-growth-factor family, with mechanistic links to satellite-cell proliferation, tissue-stress signaling, and anti-apoptotic repair pathways. The MGF E-domain increases myoblast proliferation and delays terminal differentiation - distinct from mature IGF-1 - apparently via a non-IGF-1R route. Clinical use must be framed as experimental only: FDA notes no identified human exposure data and raises immunogenicity / API-characterization concerns.
PEG-MGF is best modeled as a PEGylated synthetic MGF E-domain analog whose proposed activity draws from the IGF-1Ec / MGF E-peptide literature. A 49-bp insert in the E-domain (exon 5) causes a reading-frame shift and a distinct C-terminus whose proliferative action is not abolished by IGF-1R blockade, while full-length MGF can still directly stimulate IGF-1R at high equimolar concentrations. The major unresolved issues are receptor identity, PEGylated product heterogeneity, human PK, immunogenicity, and tumor/proliferation risk.
PEG-MGF belongs to the same IGF-1 family as the analogs elsewhere in this cluster, but it is the splice-variant / E-domain branch: a proliferation-biased "repair signal," not an anabolic IGF-1R agonist. The underlying MGF biology has credible mechanistic and animal support, but PEG-MGF itself has no validated human PK, dose, safety, efficacy, or exposure data. The page keeps the MGF biology separate from PEG-MGF human claims and frames its dosing as a speculative research scaffold.
MGF is a special, locally-made version of IGF-1 that appears after muscle stress. Its job is different from regular IGF-1: instead of telling muscle cells to grow and mature, the MGF "E-peptide" tells muscle stem cells to multiply first - building a pool of repair cells. PEG-MGF is a longer-lasting synthetic version of that signal.
MGF (IGF-1Ec) is the mechano-responsive IGF-1 splice variant. Its E-domain peptide increases satellite-cell/myoblast proliferation and delays terminal differentiation - functionally distinct from mature IGF-1, and apparently mediated by a non-IGF-1R receptor. Full-length MGF can still engage IGF-1R at high concentrations. The repair narrative is a sequential program: MGF first (proliferation), then IGF-1Ea (differentiation).
A 49-bp insert in the E-domain shifts the reading frame, producing a distinct C-terminal E-peptide whose proliferative activity is not abolished by IGF-1R blockade, implying a separate receptor. Most PEG-MGF preparations contain only the E-peptide (not the full pro-MGF with mature IGF-1), which limits IGF-1R-mediated signaling. The receptor identity, PEGylated heterogeneity, and human PK all remain unresolved.
PEG-MGF has no validated human dose, no approved therapeutic use, no established human PK, and FDA has not identified human exposure data for PEG-MGF drug products by any route. Everything below is a calculator/UI scaffold for research-education math, not treatment instructions. Working unit: micrograms (µg). No PEG-MGF dose, route, cycle, or monitoring schedule is clinically validated.
| Band | Calculator options | ~per-kg example | Basis |
|---|---|---|---|
| Low | 50-100 µg | 0.5-1.5 µg/kg | Anecdotal / nonvalidated UI scaffold |
| Standard | 100-200 µg | 1-3 µg/kg | Anecdotal / nonvalidated UI scaffold |
| High | 200-400 µg | 2-6 µg/kg | Higher-risk; should trigger a warning |
| Hard cap | >400 µg | Avoid presenting as protocol | No human safety basis |
These are calculator-data placeholders, not dosing guidance. PEG-MGF has no validated human dose.
| Body weight | Low (1 µg/kg) | Standard (2 µg/kg) | High (4 µg/kg) |
|---|---|---|---|
| 55 kg | 55 µg | 110 µg | 220 µg |
| 65 kg | 65 µg | 130 µg | 260 µg |
| 75 kg | 75 µg | 150 µg | 300 µg |
| 85 kg | 85 µg | 170 µg | 340 µg |
| 95 kg | 95 µg | 190 µg | 380 µg |
| 105 kg | 105 µg | 210 µg | 420 µg (high-warning) |
Educational interpolation only; not validated for PEG-MGF.
| Trigger | Action | Rationale |
|---|---|---|
| No human safety data (baseline) | Keep default low; show warning | FDA: no identified human exposure data |
| Injection reaction, rash, swelling, systemic allergy | HOLD / HARD STOP | Immunogenicity / anti-PEG-antibody concern |
| Active cancer, suspicious lesion, unexplained mass | HARD STOP | Growth-factor / proliferation concern |
| Uncontrolled diabetes / insulin-pathway instability | Hold / clinician review | IGF-axis overlap concern |
| Pregnancy / lactation | HARD STOP | No safety data |
| Competitive athlete | HARD STOP | WADA-prohibited class |
| Abnormal IGF-1, glucose, edema, neuropathy, severe headache | Hold / evaluate | IGF / growth-factor safety overlay |
| Marker | Why included | Validated for PEG-MGF? |
|---|---|---|
| IGF-1 | IGF-axis context | No - do not use to "optimize" PEG-MGF |
| Fasting glucose / insulin / A1c | IGF/insulin-pathway safety overlay | No |
| CBC / CMP | General systemic safety | No |
| hs-CRP | Inflammatory context | No |
| CK | Muscle-injury context | No - interpret cautiously |
| BP / edema check | Growth-factor fluid-retention concern | No |
| Cancer-screening status | Growth/proliferation caution | No - hard-stop if abnormal |
Research reconstitution arithmetic only - not a recommendation to use PEG-MGF, and not clinical dose selection. Formula: concentration = vial mg x 1000 / BAC mL (µg/mL); draw mL = target µg / concentration; U-100 units = draw mL x 100; doses = total µg / target µg.
The calculator handles reconstitution arithmetic only. It is not a recommendation to use PEG-MGF and not clinical dose selection. PEG-MGF has no validated human dose, no approved therapeutic use, no established human PK, and no identified human exposure data. Use is research-only and, in sport, prohibited.
Verify against supplier COA and mass spec; FDA cites peptide impurity / API-characterization complexity, and CAS/formula records are inconsistent.
PEGylated products vary by linker/PEG definition; the "PEG-MGF" in two vials may not be identical - confirm by MS.
Repeated PEG dosing can induce anti-PEG antibodies (accelerated clearance / hypersensitivity); a PEG-specific risk beyond the peptide.
Keep PEG-MGF distinct from IGF-1, IGF-1 LR3, and IGF-1 DES in any record - it is the splice-variant E-domain branch, not an IGF-1R agonist.
Growth-factor biology; avoid in malignancy or proliferative disorders without specialist review.
Any human-administration workflow is a hard stop - no validated protocol, and WADA-prohibited.
PEG-MGF "stacks" are practice-market concepts, not validated protocols. Pairing it with training, other repair peptides, or IGF/GH-axis agents borrows logic from adjacent literatures and compounds the uncertainty of multiple unapproved compounds. The engine treats malignancy and proliferative disorders as hard constraints because PEG-MGF is a growth-factor-related compound.
Active or suspected malignancy, unexplained mass, proliferative retinopathy, uncontrolled diabetes, pregnancy/lactation, and competitive-sport participation should all be treated as hard stops, because PEG-MGF is a growth-factor-related experimental compound and MGF-E has shown proliferation/migration/invasion effects in tumor-cell models, with no validated human safety profile and FDA immunogenicity / impurity concerns. Keep it distinct from the IGF-1 / LR3 / DES analogs - it is the splice-variant E-domain branch, not an IGF-1R agonist.
There is no robust human adverse-event dataset for PEG-MGF. FDA states it has not identified human exposure data for PEG-MGF drug products and flags immunogenicity and impurity / API-characterization concerns. Safety must therefore be inferred from mechanism, peptide-injection risk, PEGylation concerns, IGF-axis overlap, and preclinical tumor/proliferation observations. PEG-MGF carries two molecule-specific worries on top of the growth-factor class: anti-PEG immunogenicity and satellite-cell exhaustion from chronic stimulation.
| Condition | Concern | Severity |
|---|---|---|
| Active cancer / suspected malignancy | Growth-factor / proliferation risk | High |
| History of aggressive cancer (no oncology clearance) | Theoretical recurrence / proliferation concern | High |
| Competitive athlete | WADA-prohibited class | High |
| Pregnancy / lactation | No safety data | High |
| Pediatric / adolescent use | Growth-axis concern; no safety data | High |
| Autoimmune / allergic history to PEG products | PEG / immunogenicity concern | Moderate-High |
| Uncontrolled diabetes | IGF / insulin-axis overlap | Moderate-High |
| Proliferative retinopathy | Growth-factor vascular / proliferative concern | Moderate-High |
| Active infection at injection site | Injection risk | Moderate |
| Poor renal / hepatic status | Unknown clearance / safety | Moderate |
Every administration; hold if swelling, warmth, rash, or escalating pain - possible immunogenic / hypersensitivity reaction.
Baseline and periodic; hold if unstable or worsening, given the IGF/insulin-axis overlap.
Baseline/periodic for context only; do not use to "optimize" PEG-MGF - it is not a validated response marker.
Watch for fluid retention, BP rise, or shortness of breath - a growth-factor fluid-retention concern.
Baseline clinical review; hard-stop on any abnormal or suspicious finding.
Any human-administration workflow is a hard stop - no validated protocol, WADA-prohibited, and detectable in doping control.
The core biology of MGF / MGF-E has credible mechanistic and animal support - especially around muscle-precursor biology, cardiac-injury models, and neurogenesis - and even some human ex-vivo myoblast data. But PEG-MGF itself lacks validated human PK, dosing, safety, efficacy, and exposure data, so all protocol claims remain speculative and research-only. Overall human-use grade: D/P.
The MGF E-domain increased myoblast proliferation and inhibited terminal differentiation - distinct from mature IGF-1 - and the effect was not abolished by IGF-1R blockade, implying a different receptor. The foundational characterization of MGF's proliferation bias.
Full-length MGF directly stimulated IGF-1R in vitro, reaching IGF-1-like maximal activation at high equimolar concentrations but with a higher EC50 - establishing a weaker but real IGF-1R interaction for the full-length form.
MGF reduced loss of cardiac function in acute myocardial infarction, and localized delivery of the MGF E-domain peptide prevented adverse remodeling after MI - consistent anti-apoptotic, tissue-preserving signals in animals.
MGF E-peptide activated human muscle progenitor cells and increased fusion potential, with responsiveness declining at older ages - direct human-cell mechanistic data, though far from a dosing or safety basis.
MGF E-peptide regulated BMSC migration, proliferation, and differentiation, and MGF promoted neurogenesis in the aging mouse brain - broadening the repair hypothesis beyond muscle, in cell/animal models.
FDA lists PEG-MGF among bulk substances that may present significant safety risks for compounding, with no identified human exposure data, and full-length MGF has been MS-characterized for anti-doping controls - while reviews caution that even the underlying MGF concept remains a contested putative product of IGF-1 expression.
Overall evidence strength is D/P for PEG-MGF as a human-use compound. The underlying MGF / MGF-E biology has credible mechanistic and animal support (muscle-precursor proliferation, cardiac-injury protection, neurogenesis), and even some human ex-vivo myoblast data. But PEG-MGF itself lacks validated human PK, dosing, safety, efficacy, and exposure data (FDA: no identified human exposure data), and a tumor-cell proliferation signal plus PEG immunogenicity temper the risk profile. It belongs on the Atlas as a research-only IGF-1 splice-variant analog - mechanistically interesting, clinically unproven, and explicitly not a validated therapy.
| Study / source | Model | Finding | Grade |
|---|---|---|---|
| PEG-MGF human exposure | Regulatory (FDA) | No identified human exposure data by any route | D |
| Yang & Goldspink | Myoblast in vitro | E-domain ↑ proliferation, ↓ differentiation (non-IGF-1R) | P |
| Janssen et al. | Full-length MGF in vitro | Direct IGF-1R stimulation (higher EC50) | P |
| Cardiac MI models | Animal | Reduced apoptosis / adverse remodeling | C |
| Cui et al. | BMSC | Migration / proliferation / differentiation effects | P |
| Tang et al. | Aging mouse brain | Promoted neurogenesis | C |
| Kandalla et al. | Human muscle progenitors (ex vivo) | Activated cells; age-related decline in response | P |
| Osteosarcoma model | Tumor cells | ↑ proliferation / migration / invasion (safety signal) | P |
PEG-MGF is the IGF-1 splice-variant / E-domain branch of the growth-factor market - proliferation-biased and (for the E-peptide) largely non-IGF-1R. That sets it apart from the IGF-1R-agonist analogs (LR3, DES) and from the actin/angiogenesis repair peptides (BPC-157, TB-500), which share the "recovery" marketing but not the mechanism.
| Feature | PEG-MGF | IGF-1 LR3 | BPC-157 | TB-500 (TB4 frag) |
|---|---|---|---|---|
| Primary frame | Tissue-repair / muscle-regeneration analog | Long-acting IGF-1 analog | Repair-market peptide | Repair / migration peptide |
| Mechanism class | IGF-1 splice-variant E-domain (non-IGF-1R) | IGF-1R agonist | Angiogenesis / NO / injury | Actin-binding / cell migration |
| Receptor | Distinct/undefined for E-domain | IGF-1R | Multiple proposed | Actin / migration biology |
| Evidence tier | P/C; no validated human PEG-MGF data | P/C (research) | Mostly animal/preclinical | Preclinical / limited |
| Regulatory status | Not approved; FDA safety-risk flag; WADA banned | Not approved; WADA banned | Not FDA-approved | Not broadly approved; WADA banned |
| Key caution | Proliferation/tumor; anti-PEG immunogenicity | Oncogenic-bypass; no human data | Gray-market quality | Proliferation / quality |